T. Rowe Price Associates’s Soleno Therapeutics SLNO Stock Holding History

T. Rowe Price Associates’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,025,937	Closed	-$34.4M	–	3323
2026 Q1	$34.4M	Sell	1,025,937 -2,292,761	-69%	-$89.9M	﹤0.01%	890
2025 Q4	$154M	Sell	3,318,698 -584,208	-15%	-$32M	0.02%	536
2025 Q3	$264M	Buy	3,902,906 +441,424	+13%	+$32.7M	0.03%	395
2025 Q2	$290M	Buy	3,461,482 +1,061,064	+44%	+$79.4M	0.03%	360
2025 Q1	$172M	Buy	2,400,418 +769,700	+47%	+$37.5M	0.02%	454
2024 Q4	$73.3M	Buy	1,630,718 +321,223	+25%	+$16.6M	0.01%	645
2024 Q3	$66.1M	Buy	1,309,495 +831,643	+174%	+$39.8M	0.01%	675
2024 Q2	$19.5M	Buy	477,852 +325,232	+213%	+$13.8M	﹤0.01%	967
2024 Q1	$6.53M	Buy	+152,620	New	+$6.9M	﹤0.01%	1171

T. Rowe Price Associates's SLNO Position: Q2 2026 in Review

T. Rowe Price Associates sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,025,937 shares — an estimated $34.4M sold.

T. Rowe Price Associates first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $290M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

T. Rowe Price Associates reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
T. Rowe Price Associates sold 1,025,937 Soleno Therapeutics shares in Q2 2026, an estimated $34.4M.
T. Rowe Price Associates first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
T. Rowe Price Associates's Soleno Therapeutics position peaked at $290M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.